Shares of Masimo Co. (NASDAQ:MASI) have received an average recommendation of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $97.17.

A number of research analysts have recently commented on the stock. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $98.00 target price for the company in a report on Thursday, November 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $108.00 target price on shares of Masimo in a report on Friday, November 3rd. BidaskClub cut shares of Masimo from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Finally, BTIG Research raised shares of Masimo from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Monday, August 14th.

Shares of Masimo (NASDAQ:MASI) opened at $88.88 on Monday. Masimo has a 52-week low of $60.31 and a 52-week high of $104.71. The firm has a market cap of $4,592.52, a PE ratio of 34.05, a P/E/G ratio of 2.99 and a beta of 0.73.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.17. The firm had revenue of $193.69 million during the quarter, compared to analysts’ expectations of $189.01 million. Masimo had a net margin of 45.83% and a return on equity of 22.17%. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 earnings per share. equities analysts predict that Masimo will post 2.95 earnings per share for the current fiscal year.

In other news, EVP Yongsam Lee sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total value of $449,450.00. Following the completion of the transaction, the executive vice president now owns 74,000 shares of the company’s stock, valued at $6,651,860. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven Barker sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 73,249 shares of the company’s stock, valued at approximately $6,592,410. The disclosure for this sale can be found here. Insiders sold 28,976 shares of company stock valued at $2,599,324 in the last ninety days. 16.60% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Masimo by 7.5% during the 2nd quarter. BlackRock Inc. now owns 7,915,230 shares of the medical equipment provider’s stock valued at $721,710,000 after purchasing an additional 550,995 shares during the period. Vanguard Group Inc. increased its position in Masimo by 6.9% during the 2nd quarter. Vanguard Group Inc. now owns 4,935,693 shares of the medical equipment provider’s stock valued at $450,036,000 after purchasing an additional 318,060 shares during the period. State Street Corp increased its position in Masimo by 10.4% during the 2nd quarter. State Street Corp now owns 1,547,728 shares of the medical equipment provider’s stock valued at $141,121,000 after purchasing an additional 146,212 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Masimo by 3.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,113,113 shares of the medical equipment provider’s stock valued at $101,494,000 after purchasing an additional 38,991 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its position in Masimo by 27.1% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,095,353 shares of the medical equipment provider’s stock valued at $99,872,000 after purchasing an additional 233,412 shares during the period. 83.71% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/04/masimo-co-masi-given-consensus-recommendation-of-hold-by-analysts.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with MarketBeat.com's FREE daily email newsletter.